Previous Article | Next Article ![]()
Journal of Virology, June 2005, p. 6969-6975, Vol. 79, No. 11
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.11.6969-6975.2005
Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
Received 30 November 2004/ Accepted 29 January 2005
|
|
|---|
|
|
|---|
VZV ORF4 transcripts have been detected in latently infected human ganglia by in situ hybridization (15). In one study 17% of trigeminal ganglia from nonimmunocompromised persons contained ORF4 RNA (14). VZV ORF4 protein is present in the cytoplasm of neurons during latency and localizes in the nucleus during reactivation (19). VZV ORF4 mRNA has been detected in experimentally infected rat ganglia (29). ORF4 transcripts and protein were detected in an in vitro model of latency in which guinea pig enteric neurons had been infected with cell-free VZV (2).
ORF4 encodes an immediate-early (IE) protein that transactivates expression of certain putative immediate-early, early, and late VZV genes (8, 9, 23). The protein acts in concert with the ORF62 protein to transactivate multiple viral promoters (26). ORF4 protein likely works at both the transcriptional and posttranscriptional levels (9). Transcriptional activation requires dimerization of the ORF4 protein (1). ORF4 protein interacts with VZV ORF62 protein, the TATA binding protein, transcription factor IIB, and NF-
B subunits p50 and p65 (11, 34).
VZV ORF4 encodes an approximately 51-kDa phosphoprotein (25), which is present in the virion tegument (17). VZV ORF4 protein is present in the nucleus early in infection and later localizes predominantly to the cytoplasm. When ORF4 protein is coexpressed with ORF62 protein, the former localizes to the nucleus (10, 27).
Since VZV ORF4 is expressed during latency, we constructed an ORF4 knockout virus to determine if the protein is important for latent infection. Here we show that ORF4 is essential for infection, that it cannot be complemented by HSV-1 ICP27, and that it has an important role for establishment of latency.
|
|
|---|
A baculovirus expressing ORF4 was constructed by inserting the ORF4 gene into plasmid pAc-CMV (37), which contains the human cytomegalovirus (CMV) IE promoter inserted into the XhoI-BamHI sites of pAcSG2 (PharMingen). Oligonucleotides ATAAGAGATGCGGCCGCTAAACTATATGGCCTCTGCTTCAATTCCA and CCCAAGCTTGGTTAGCAGTTAAGGTACTACA were used to amplify ORF4 from VZV cosmid NotI A (3) using PCR. The PCR product was blunted with T4 DNA polymerase and inserted into pAc-CMV after the latter had been cut with BglII and blunted with the Klenow fragment of Escherichia coli DNA polymerase I to yield plasmid pAC-CMV4. Recombinant baculovirus was produced by cotransfecting Sf9 cells with plasmid pAC-CMV4 and BaculoGold-linearized baculovirus DNA (PharMingen). Recombinant baculovirus was plaque purified on Sf9 cells, and the resulting virus, Baculo 4, was amplified and concentrated by centrifugation at 8,800 x g for 2 h and then resuspended in phosphate-buffered saline containing 1% fetal bovine serum. The titers of Baculo 4 and control baculovirus, Autographa californica multiple nucleopolyhedrovirus, were determined in Sf9 cells.
VZV cosmids and transfections. VZV cosmids NotI A, NotI BD, MstII A, and MstII B encompass the VZV genome (Fig. 1) and recombine after transfection to produce infectious virus. VZV ORF4 is located between nucleotides 2,786 and 4,141 of the viral genome (7). To produce VZV deleted for ORF4, plasmid NS (3), which contains VZV nucleotides 1 to 11433, was cut with XcmI, which cuts at VZV nucleotides 2,884 and 4,226. The large fragment, which lacks most of ORF4, was ligated to itself to produce plasmid NS-4D. Plasmid NS-4D was cut with NotI and SacI, and the large fragment deleted for most of ORF4 was inserted in place of the corresponding region in cosmid NotI A. The resulting cosmid, NotI A-4D, has a deletion beginning 85 nucleotides upstream of codon 1 and ending at codon 419 (Fig. 1).
![]() View larger version (11K): [in a new window] |
FIG. 1. Construction of recombinant VZV with a deletion in ORF4. The VZV genome is 124,884 bp in length (line 1) and contains unique long (UL), unique short (US), internal repeat (IR), and terminal repeat (TR) regions (line 2). The four cosmids used to produce infectious virus span the VZV genome (lines 3 and 4). Cosmid NotI A-4D (line 5) is deleted for codons 1 to 419 of ORF4.
|
A rescued ORF4 deletion virus was constructed using a DNA fragment that contains ORF4 and additional flanking sequences. A plasmid containing a PvuII fragment of VZV (VZV nucleotides 2048 to 5039) was cut with PvuII, and the 3.0-kb fragment containing ORF4 was isolated. Melanoma cells were cotransfected with 1 µg of the DNA fragment containing ORF4, 50 ng of pCMV62, and 2 µg of virion DNA from the ORF4 deletion mutant. After CPE was observed, cell-free virus was prepared by sonication of the cells followed by centrifugation. Serial dilutions of the supernatant were used to infect melanoma cells. Cells containing CPE from the highest dilution of supernatant were used for additional rounds of plaque purification.
Southern blotting, immunoblotting, and growth analysis of VZV. Viral DNA was purified from nucleocapsids, cut with BamHI or PvuII, fractionated on 0.8% agarose gels, transferred to nylon membranes, and probed with a [32P]dCTP-radiolabeled DNA fragment that contains ORF4.
Immunoblotting was performed using cell lysates from melanoma cells infected with parental or ORF4 mutant VZV. The blots were incubated with rabbit antibody to ORF4 protein (23) followed by horseradish peroxidase-conjugated anti-rabbit antibody and developed using enhanced chemiluminescence (Pierce Chemical Company, Rockford, Ill.).
Melanoma cells in 25-cm2 flasks were infected with about 200 PFU of VZV mutants. The following 5 consecutive days, cells were treated with trypsin and serial dilutions were used to infect melanoma cells. Seven days after infection, the cells were fixed with crystal violet stain and the number of plaques was determined.
Virus complementation studies. Vero and Vero 3-3 cells (expressing HSV-1 ICP27) were infected for 3 days with cell-associated ROka4D, ROka4DR, or cell-free HSV-1 5dl1.2. Cells infected with HSV-1 5dl1.2 were then scraped, and cell lysates and media were frozen and thawed three times. The material was pelleted, the supernatant containing intracellular and supernatant virus was saved, and serial dilutions of virus were incubated on Vero 3-3 cells for 2 h. The virus was then removed, and medium containing 0.5% human immunoglobulin (Gammagard; Baxter Healthcare Corp., Glendale, Calif.) was added. Three days later, the medium was removed, the cells were fixed with crystal violet, and plaques were counted. Vero or Vero 3-3 cells infected with VZV for 3 days were washed and treated with trypsin, and titers of virus-infected cells were determined on MeWo or MeWo cells infected with Baculo 4. One week later, the medium was removed, the cells were fixed with crystal violet, and plaques were counted.
Animal experiments. Female cotton rats, 4 to 6 weeks of age, were anesthetized and inoculated intramuscularly along the thoracic and lumbar spine with VZV. Six sites on each side of the spine were injected with 1.75 x 105 PFU of cell-associated VZV per site. Three days after inoculation (acute infection) or five to six weeks after inoculation (latent infection), animals were sacrificed and thoracic and lumbar dorsal root ganglia were isolated. For acute infection experiments, seven animals were infected with ROka4D and six were infected with ROka4DR. For latency experiments, 10 cotton rats were inoculated with either ROka4D or ROka in the first experiment and 10 animals were infected with ROka4D and 9 were infected with ROka4DR in the second experiment. DNA was purified from pooled ganglia from each animal using a Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN). PCR was performed using 500 ng of ganglia DNA and ORF21 primers as described previously (31). Serial dilutions of VZV cosmid NotI A in 500 ng of ganglion DNA from uninfected cotton rats were used in PCRs to estimate the copy number of latent viral DNA. The PCR products were fractionated on a 1% agarose gel, transferred to nylon membranes, and hybridized with a [32P]dCTP-radiolabeled ORF21 probe. The VZV copy numbers in latently infected ganglia were estimated using a phosphorimager. The lower limit of detection was 10 copies of VZV DNA per 500 ng of cotton rat ganglion DNA.
PCR was also performed with ganglion DNA and primers for ORF4, CATAAAGTCTTCACAAATAG and TATGCATTACGAACAAAGGG, which are located in the region of ORF4 deleted in the VZV mutant. After separation of the PCR products on agarose gels and transfer to nylon membranes, the blots were probed with a [32P]dCTP-radiolabeled ORF4 probe.
RNA was isolated from ganglia by homogenization in Trizol (Invitrogen, Carlsbad, Calif.), treated with DNase I, and heated to inactivate DNase I, and cDNA was prepared using reverse transcriptase. PCR was performed with the cDNA using primers specific for ORF63 and ORF40 as described previously (4, 32), followed by electrophoresis of the PCR products, blotting onto nylon membranes, and hybridization to ORF63 and ORF40 radiolabeled probes.
Statistics. Statistical results were obtained using StatXact from Cytel Software Corporation (Cambridge, MA). P values were computed using exact permutation tests, which for individual 2-by-2 tables correspond to Fisher's exact test. An overall stratified analysis, using the mid-P-value adjusted exact permutation test for the common odds ratio, was performed to jointly assess the differences in VZV latency between the ORF4 mutant virus versus the two control viruses (ROka and ROka4DR) from the two independent animal experiments.
|
|
|---|
To produce cultured cells that could complement the deletion in VZV ORF4, we first constructed a baculovirus, Baculo 4, which expresses VZV ORF4 in melanoma cells. Baculo 4 contains VZV ORF4 driven by the human IE cytomegalovirus promoter. Sf9 insect or melanoma cells infected with Baculo 4 expressed proteins of 52 and 58 kDa that reacted with ORF4 antibody; the 52-kDa protein is similar in size to the protein expressed in melanoma cells infected with VZV or cells transfected with a vector expressing ORF4 (Fig. 2). Melanoma cells infected with Baculo 4 at a multiplicity of infection (MOI) of 50 showed no CPE.
![]() View larger version (74K): [in a new window] |
FIG. 2. Expression of VZV ORF4 protein in melanoma cells by baculovirus expressing ORF4. Melanoma cells were infected with control baculovirus, baculovirus expressing ORF4 protein (Baculo 4), or VZV ROka or were transfected with a plasmid expressing ORF4 (pCMV-ORF4). Sf9 cells were infected with control baculovirus, Baculo 4, or were not infected. Lysates were prepared and immunoblotted with antibody to ORF4 protein. Cells infected with Baculo 4 have proteins of 52 and 58 kDa that react with ORF4 protein antibody; cells infected with VZV or transfected with ORF4 have a 52-kDa protein that reacts with the antibody (arrowhead).
|
Southern blotting was performed to confirm that ROka4D had the expected genome configuration. Digestion of VZV ROka and ROka4D with BamHI followed by hybridization with a probe corresponding to the whole VZV genome showed similar patterns of bands (data not shown). Digestion of VZV ROka (parental virus) with PvuII yielded a 3.0-kb fragment, while digestion of VZV ROka4D with PvuII resulted in a 1.6-kb fragment due to the deletion in ORF4 (Fig. 3).
![]() View larger version (28K): [in a new window] |
FIG. 3. Southern blot of virion DNA from cells infected with VZV ROka, ORF4 deletion mutant (ROka4D), or ORF4-rescued virus (ROka4DR). Virion DNAs were digested with PvuII and hybridized to a probe that contains ORF4. Numbers correspond to the size of DNAs in kb pairs.
|
![]() View larger version (40K): [in a new window] |
FIG. 4. Immunoblot of ORF4 and gE expression in melanoma cells. Cells were infected with ROka or ROka4D in the presence of Baculo 4 (ROka4D), ROka4D after one passage in cells without Baculo 4 (ROka4D P1), or ROka4D after two passages in cells without Baculo 4 (ROka4D P2) (A, B). Blots were incubated with antibody to ORF4 protein (A) or gE (B). Proteins of 52 and 58 kDa that react with antibody to ORF4 protein are present in cells infected with Baculo 4 and VZV; a 52-kDa protein reacts with the antibody in cells infected with VZV alone (ROka, ROka4DR). Proteins of 70 to 90 kDa react with antibody to VZV gE. Equivalent amounts of lysates were loaded in panels A and B. Immunoblot of ORF4 protein in cells infected with ROka or ROka4DR (C, D). Blots were incubated with antibody to ORF4 protein (C) or gE (D). Numbers correspond to the size of proteins in kilodaltons.
|
To verify that ROka4DR had the expected genome structure, viral DNA was digested with BamHI or PvuII. Digestion of VZV ROka and ROka4DR with BamHI followed by hybridization with a probe corresponding to the whole VZV genome showed identical patterns of bands (data not shown). Digestion of VZV ROka and ROka4DR with PvuII yielded a 3.0-kb DNA fragment, confirming that the deleted DNA had been restored (Fig. 3). To verify that ROka4DR could express ORF4, melanoma cells were infected with VZV ROka or ROka4DR. Similar levels of ORF4 protein were detected in cells infected with either virus (Fig. 4C, D).
Growth of VZV ORF4 deletion mutant in cell culture. Melanoma cells were infected with the ORF4 deletion mutant virus, rescued virus, or parental virus, and over a 5-day period, virus titers were determined. While ROka and ROka4DR grew to similar titers that peaked at day 3, ROka4D was unable to grow on melanoma cells (Fig. 5). Thus, ORF4 is essential for growth of VZV in cell culture in the absence of Baculo 4.
![]() View larger version (20K): [in a new window] |
FIG. 5. Growth of VZV ROka, ROka4D, and ROka4DR in melanoma cells in the absence of Baculo 4. Cells were infected with the indicated viruses, and each day after infection, the cells were treated with trypsin and the virus titers were determined.
|
To further evaluate whether ICP27 can complement VZV ORF4, we infected Vero and Vero 3-3 cells with ROka4D, ROka4DR, or HSV-1 5dl1.2. While Vero 3-3 cells complemented the growth of HSV-1 5dl1.2, the cells did not complement the growth of ROka4D (Table 1). HSV-1 5dl1.2 did not produce plaques on melanoma cells or melanoma cells infected with Baculo 4. Thus, HSV-1 ICP27 could not complement VZV ORF4, and ORF4 failed to complement ICP27.
|
View this table: [in a new window] |
TABLE 1. Single-step growth study of VZV ROka4D, ROka4DR, or HSV-1 ICP27 deletion mutant 5dl1.2 on Vero cells or 3-3 cellsa
|
![]() View larger version (12K): [in a new window] |
FIG. 6. Estimated copy number of VZV genomes in latently infected cotton rat ganglia from animals infected with ROka or ROka4D (A) or from animals infected with ROka4DR or ROka4D (B). The geometric mean number of VZV genome copies per 500 ng of ganglia DNA in PCR-positive ganglia is shown at the bottom of the figure. The limit of detection is 10 copies of VZV DNA per 500 ng of ganglion DNA (horizontal line).
|
![]() View larger version (33K): [in a new window] |
FIG. 7. Southern blot for ORF4 in ganglia of cotton rats latently infected with ROka or ROka4D grown in the absence of baculovirus expressing ORF4. VZV cosmids NotI A and NotI A-4D are positive and negative controls, respectively. VZV DNA was amplified by PCR using ORF4 primers and hybridized to an ORF4 probe. An arrowhead shows the size of the ORF4 PCR product.
|
![]() View larger version (36K): [in a new window] |
FIG. 8. RNA transcripts corresponding to ORF63 in animals latently infected with ROka4D, ROka4DR, or ROka. RNA was isolated from ganglia and treated with DNase I, cDNA was synthesized with reverse transcriptase, cDNA was amplified by PCR using ORF63, and Southern blotting was done using a radiolabeled probe. ORF63 transcripts are detected in animal 4 infected with ROka4D, animal 7 infected with ROka4DR, and animal 9 infected with ROka. The positions of markers indicating the size of DNA in base pairs are shown to the left of the gel.
|
|
View this table: [in a new window] |
TABLE 2. Frequency of animals with VZV-infected ganglia and mean copy numbers after acute infection with VZV ROka4D or ROka4DR
|
|
|
|---|
Cells infected with baculovirus expressing ORF4 complemented the growth of the VZV ORF4 deletion mutant. In contrast, the VZV ORF4 deletion mutant was not complemented in cells expressing HSV-1 ICP27, the homolog of ORF4. Similarly, cells infected with baculovirus expressing ORF4 did not complement the growth of the HSV-1 ICP27 deletion mutant. Prior experiments showed that Vero cells lines stably expressing VZV ORF4 weakly complemented the growth of HSV-1 ICP27 deletion or temperature-sensitive mutants (23). In addition, VZV coinfection of human embryonic fibroblasts complemented a temperature-sensitive ICP27 mutant only threefold (12). Since HSV-1 ICP27 is a larger protein (512 amino acids) than VZV ORF4 protein (452 amino acids), it was possible that the HSV-1 protein might complement the VZV protein, even though the latter could not efficiently complement the former. However, a stable cell line expressing ICP27 did not complement the VZV ORF4 deletion mutant.
The carboxy portion of ORF4, which has a zinc finger domain, contains the region of the protein most conserved with HSV-1 ICP27. Deletion of the carboxy termini of HSV-1 ICP27 and ORF4 protein abolishes their transactivating activity (24). Fusion of the carboxy terminus of ORF4 to the remainder of ICP27 or fusion of the carboxy terminus of ICP27 to the remainder of ORF4 protein fails to restore their transactivating functions. Thus, one possible reason for the inability of ICP27 to complement the ORF4 deletion mutant virus is that ICP27 cannot adequately complement the transactivating activity of ORF4. Alternatively, since ORF4 protein is located in the virion tegument, while ICP27 is not in the virion (36), it is possible that a structural function of ORF4 protein cannot be complemented by HSV-1 ICP27.
ORF4 binds to the ORF62 protein, especially to a hypophosphorylated form of ORF62 protein (34). While ORF62 is highly phosphorylated in infected cells, the protein is less phosphorylated when localized in the viral tegument. The binding of ORF4 to ORF62 may be important for localization of the two proteins in the tegument. Thus, deletion of ORF4 may impair a structural activity of ORF62. Alternatively, since ORF4 augments the transactivating function of ORF62 (26), ORF4 may be critical for ORF62 to exert its full transregulatory activities.
At least six VZV genes are expressed during latency in human ganglia, and five of these genes have been shown to be expressed in rodent ganglia. Prior studies showed that VZV ORF66 and ORF21, which are expressed during latency, are dispensable for latent infection (33, 35). In contrast, ORF63 is critical for latency (4). Thus, ORF4 is the second gene that has been shown to be important for establishment of latency. In contrast to VZV ORF4, HSV-1 ICP27 is not expressed during latency.
HSV-1 deleted for ICP27 is severely impaired for establishment of latency (13). Infection of mice with an HSV-1 ICP27 deletion mutant (d27-1) or wild-type HSV-1 showed 1,000-fold-less ICP27 mutant virus in the ganglia of latently infected mice than that in animals infected with wild-type virus. Similarly, infection of mice with another ICP27 deletion mutant (5dl1.2) failed to result in detectable virus in ganglia 30 days after infection, and virus could not be reactivated in the presence of a complementing cell line (18). We found that while significantly fewer animals were latently infected with the VZV ORF4 deletion mutant than the control viruses, the geometric mean copy number of VZV genomes in latently infected animals was similar in animals infected with the ORF4 deletion mutant and control viruses. Taken together, these studies emphasize the differences in VZV ORF4 and HSV-1 ICP27 and underscore the necessity of studying the biology of both of these important human viruses.
Present address: Chesapeake-PERL Inc., 8510A Corridor Road, Savage, MD 20763. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»